title: Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer.
abstract: BACKGROUND
  Goserelin plus aromatase inhibitors (AI) have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.
  
  
  METHODS
  Here we report a case of long-term (3 years) response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.
  
  
  CONCLUSIONS
  Goserelin plus endocrine treatments may benefit male breast cancer.
authors.forename: Hang
authors.initials: H
authors.lastname: Jiang
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Breast Oncology, 307 Hospital of PLA, Beijing 100071, China. jiangzefei@medmail.com.cn.
authors.forename: Zefei
authors.initials: Z
authors.lastname: Jiang
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D018567:Breast Neoplasms, Male / Q000188:drug therapy* / Q000473:pathology; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003280:Contraceptives, Oral, Synthetic; D017273:Goserelin; D008525:Medroxyprogesterone